Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Amgen
Amgen
Investors in AbbVie, Lilly, Amgen and more set to vote on executive pay, drug pricing
Fierce Pharma
Tue, 03/27/18 - 10:00 pm
AbbVie
Eli Lilly
Amgen
executive pay
drug pricing
Amgen and Allergan Hopeful that Herceptin Biosimilar Approval Will Be Around the Corner
Xtalks
Mon, 03/26/18 - 09:36 am
Amgen
Allergan
Herceptin
biosimilars
ABP 980
CHMP
EMA
Roche
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
Thu, 03/22/18 - 09:21 am
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Why Amgen Shouldn't Use Its War Chest For A Celgene Megamerger
Investors Business Daily
Mon, 03/19/18 - 12:07 pm
Amgen
Celgene
M&A
Alexion
AstraZeneca
Drug companies are beginning to wake up to this new risk factor
Marketwatch
Mon, 03/19/18 - 12:05 pm
pharma industry
co-pay coupons
Pfizer
Sanofi
Amgen
Novartis
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Tue, 03/13/18 - 09:30 pm
Amgen
Repatha
Sensipar
generics
Sanofi
Regeneron
Praluent
Top 5 boards for week ending March 10, 2018
CP Wire
Sun, 03/11/18 - 03:05 pm
Daiichi Sankyo
Shire
Amgen
Sanofi
AstraZeneca
FDA Approves First Generic Versions of Amgen’s Sensipar
RAPS.org
Thu, 03/8/18 - 07:27 pm
FDA
generics
Amgen
Sensipar
Cipla
Aurobindo
Top 5 viewed boards for week ending March 3, 2018
CP Wire
Sun, 03/4/18 - 01:50 pm
cafepharma
Daiichi Sankyo
Shire
Allergan
Amgen
Sanofi
sales meeting
layoffs
Esmya
Pfizer
Celgene
M&A
Top drugmakers are counting on two hot drug fields—migraine and NASH—but payers are ready to rumble
Fierce Pharma
Thu, 02/22/18 - 11:28 pm
migraines
NASH
Amgen
Eli Lilly
Teva Pharmaceutical
Allergan
Gilead Sciences
Novo Nordisk
Intercept Pharma
PBMs
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
Forbes
Sun, 02/18/18 - 10:16 am
cholesterol
PCSK9 inhibitors
Sanofi
Regeneron
Praluent
Amgen
Repatha
3 Tough Questions for Amgen
Motley Fool
Thu, 02/15/18 - 09:37 am
Amgen
payers
cash
margins
Amgen still far from performing an important acquisition
GoinPharma
Sun, 02/11/18 - 06:23 pm
Amgen
M&A
Amgen Q4 Earnings Results: 2 Things to Hate and 2 Things to Like
Motley Fool
Sun, 02/4/18 - 11:45 am
Amgen
earnings
Amgen reports profit below analyst views, but beats expectations on earnings outlook
CNBC
Fri, 02/2/18 - 09:33 am
Amgen
earnings
Amgen’s $70B in ‘deal capacity’ post-tax reform puts the spotlight on ‘big things’ in M&A — analyst
Endpoints
Fri, 02/2/18 - 09:31 am
Amgen
tax reform
M&A
What to Expect From Amgen, Inc. in 2018
Motley Fool
Sun, 01/21/18 - 10:40 am
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
Amgen kicks off 2018 with double the good news for slow-growing Kyprolis
Fierce Pharma
Thu, 01/18/18 - 10:30 pm
Amgen
Kyprolis
Multiple Myeloma
Will 2018 Be Amgen Inc.'s Best Year Yet?
Motley Fool
Wed, 01/17/18 - 10:08 am
Amgen
Enbrel
Aranesp
Neulasta
Epogen
5 Things Amgen's CEO Just Said That Investors Need to Know
Motley Fool
Wed, 01/10/18 - 10:13 am
Amgen
Pharma CEOs
Bob Bradway
Prolia
M&A
Pages
« first
‹ previous
…
28
29
30
31
32
33
34
35
36
…
next ›
last »